Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Bosso

Showing results (11-20 of 75) with videos related to

Pageof 8
Sort By:
Journal of Clinical Pharmacy and Therapeutics|October 1, 1992
Advances in the pharmacotherapy of cystic fibrosisJ A Bosso
Drug Intelligence & Clinical Pharmacy|October 1, 1984
Should pulmonary exacerbations in cystic fibrosis be treated with antibiotics?J A Bosso
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 1, 1997
Controlling pneumococcal resistance to penicillinJ A Bosso
DICP : the Annals of Pharmacotherapy|July 1, 1989
Bacterial resistance to antibiotics: mechanisms and prevalence in hospitals and nursing homesJ A Bosso
Texas Heart Institute Journal|January 1, 1990
Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazoleJ A Bosso, R A Prince
The Pediatric Infectious Disease Journal|March 1, 1988
Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosisJ A Bosso, P G Black
Clinical Pharmacokinetics|June 1, 1993
Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerationsC A Lindsay, J A Bosso
Clinical Pharmacy|December 1, 1988
Lack of correlation between objective indicators and clinical-response scores during antimicrobial therapy for acute pulmonary exacerbations of cystic fibrosisJ A Bosso, K B Walker
International Journal of Clinical Practice|June 17, 2011
Application of antimicrobial stewardship to optimise management of community acquired pneumoniaJ A Bosso, R H Drew
Drug Intelligence & Clinical Pharmacy|April 1, 1986
Norfloxacin: a quinoline antibioticD A Marble, J A Bosso
Pageof 8

Showing results (11-20 of 75) with videos related to

Sort By:
Pageof 8
Journal of Clinical Pharmacy and Therapeutics|October 1, 1992
Advances in the pharmacotherapy of cystic fibrosisJ A Bosso
Drug Intelligence & Clinical Pharmacy|October 1, 1984
Should pulmonary exacerbations in cystic fibrosis be treated with antibiotics?J A Bosso
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 1, 1997
Controlling pneumococcal resistance to penicillinJ A Bosso
DICP : the Annals of Pharmacotherapy|July 1, 1989
Bacterial resistance to antibiotics: mechanisms and prevalence in hospitals and nursing homesJ A Bosso
Texas Heart Institute Journal|January 1, 1990
Anti-anaerobic antimicrobial agents: cefoxitin, cefotetan, clindamycin, and metronidazoleJ A Bosso, R A Prince
The Pediatric Infectious Disease Journal|March 1, 1988
Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosisJ A Bosso, P G Black
Clinical Pharmacokinetics|June 1, 1993
Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerationsC A Lindsay, J A Bosso
Clinical Pharmacy|December 1, 1988
Lack of correlation between objective indicators and clinical-response scores during antimicrobial therapy for acute pulmonary exacerbations of cystic fibrosisJ A Bosso, K B Walker
International Journal of Clinical Practice|June 17, 2011
Application of antimicrobial stewardship to optimise management of community acquired pneumoniaJ A Bosso, R H Drew
Drug Intelligence & Clinical Pharmacy|April 1, 1986
Norfloxacin: a quinoline antibioticD A Marble, J A Bosso
Pageof 8